Mahesh Thirunavukkarasu1, Seetur R Pradeep1, Gopi Ukani2, Salim Abunnaja2, Mark Youssef2, Diego Accorsi2, Santosh Swaminathan2, Sue Ting Lim2, Virginia Parker2, Jacob Campbell1, Muhammad Tipu Rishi2, J Alexander Palesty3, Nilanjana Maulik4. 1. Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA. 2. Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA. 3. Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA. 4. Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA. Electronic address: nmaulik@uchc.edu.
Abstract
OBJECTIVES: In the United States, over 8.5 million people suffer from peripheral arterial disease (PAD). Previously we reported that Pellino-1(Peli1) gene therapy reduces ischemic damage in the myocardium and skin flaps in Flk-1 [Fetal Liver kinase receptor-1 (Flk-1)/ Vascular endothelial growth factor receptor-2/VEGFR2] heterozygous (Flk-1+/--) mice. The present study compares the angiogenic response and perfusion efficiency following hind limb ischemia (HLI) in, Flk-1+/- and, MAPKAPKINASE2 (MK2-/-) knockout (KO) mice to their control wild type (WT). We also demonstrated the use of Peli1 gene therapy to improve loss of function following HLI. STUDY DESIGN AND METHODS: Femoral artery ligation (HLI) was performed in both Flk-1+/- and MK2-/- mice along with their corresponding WT. Another set of Flk-1+/- and MK2-/- were injected with either Adeno-LacZ (Ad.LacZ) or Adeno-Peli1 (Ad.Peli1) after HLI. Hind limb perfusion was assessed by laser doppler imaging at specific time points. A standardized scoring scale is used to quantify the extent of ischemia. Histology analysis performed includes capillary density, fibrosis, pro-angiogenic and anti-apoptotic proteins. RESULTS: Flk-1+/- and MK2-/- had a slower recovery of perfusion efficiency in the ischemic limbs than controls. Both Flk-1+/- and MK2-/- KO mice showed decreased capillary density and capillary myocyte ratios with increased fibrosis than their corresponding wild types. Ad.Peli1 injected ischemic Flk-1+/- limb showed improved perfusion, increased capillary density, and pro-angiogenic molecules with reduced fibrosis compared to Ad.LacZ group. No significant improvement in perfusion was observed in MK2-/- ischemic limb after Ad. Peli1 injection. CONCLUSION: Deletion of Flk-1 and MK2 impairs neovascularization and perfusion following HLI. Treatment with Ad. Peli1 results in increased angiogenesis and improved perfusion in Flk-1+/- mice but fails to rectify perfusion in MK2 KO mice. Overall, Peli1 gene therapy is a promising candidate for the treatment of PAD.
OBJECTIVES: In the United States, over 8.5 million people suffer from peripheral arterial disease (PAD). Previously we reported that Pellino-1(Peli1) gene therapy reduces ischemic damage in the myocardium and skin flaps in Flk-1 [Fetal Liver kinase receptor-1 (Flk-1)/ Vascular endothelial growth factor receptor-2/VEGFR2] heterozygous (Flk-1+/--) mice. The present study compares the angiogenic response and perfusion efficiency following hind limb ischemia (HLI) in, Flk-1+/- and, MAPKAPKINASE2 (MK2-/-) knockout (KO) mice to their control wild type (WT). We also demonstrated the use of Peli1 gene therapy to improve loss of function following HLI. STUDY DESIGN AND METHODS: Femoral artery ligation (HLI) was performed in both Flk-1+/- and MK2-/- mice along with their corresponding WT. Another set of Flk-1+/- and MK2-/- were injected with either Adeno-LacZ (Ad.LacZ) or Adeno-Peli1 (Ad.Peli1) after HLI. Hind limb perfusion was assessed by laser doppler imaging at specific time points. A standardized scoring scale is used to quantify the extent of ischemia. Histology analysis performed includes capillary density, fibrosis, pro-angiogenic and anti-apoptotic proteins. RESULTS: Flk-1+/- and MK2-/- had a slower recovery of perfusion efficiency in the ischemic limbs than controls. Both Flk-1+/- and MK2-/- KO mice showed decreased capillary density and capillary myocyte ratios with increased fibrosis than their corresponding wild types. Ad.Peli1 injected ischemic Flk-1+/- limb showed improved perfusion, increased capillary density, and pro-angiogenic molecules with reduced fibrosis compared to Ad.LacZ group. No significant improvement in perfusion was observed in MK2-/- ischemic limb after Ad. Peli1 injection. CONCLUSION: Deletion of Flk-1 and MK2 impairs neovascularization and perfusion following HLI. Treatment with Ad. Peli1 results in increased angiogenesis and improved perfusion in Flk-1+/- mice but fails to rectify perfusion in MK2 KO mice. Overall, Peli1 gene therapy is a promising candidate for the treatment of PAD.
Authors: K Maruyama; Y Mori; S Murasawa; H Masaki; N Takahashi; Y Tsutusmi; Y Moriguchi; Y Shibazaki; Y Tanaka; M Shibuya; M Inada; H Matsubara; T Iwasaka Journal: J Mol Cell Cardiol Date: 1999-03 Impact factor: 5.000
Authors: Muhammad T Rishi; Vaithinathan Selvaraju; Mahesh Thirunavukkarasu; Inam A Shaikh; Kotaro Takeda; Guo-Hua Fong; J Alexander Palesty; Juan A Sanchez; Nilanjana Maulik Journal: Microvasc Res Date: 2014-11-03 Impact factor: 3.514
Authors: Chandra K Rednam; Rickesha L Wilson; Vaithinathan Selvaraju; Muhammad T Rishi; Mahesh Thirunavukkarasu; Vladimir Coca-Soliz; Rajesh Lakshmanan; John A Palesty; David W McFadden; Nilanjana Maulik Journal: Microcirculation Date: 2017-08 Impact factor: 2.628
Authors: S Takeshita; L P Zheng; E Brogi; M Kearney; L Q Pu; S Bunting; N Ferrara; J F Symes; J M Isner Journal: J Clin Invest Date: 1994-02 Impact factor: 14.808
Authors: Orit Harari-Steinberg; Sally Metsuyanim; Dorit Omer; Yehudit Gnatek; Rotem Gershon; Sara Pri-Chen; Derya D Ozdemir; Yaniv Lerenthal; Tzahi Noiman; Herzel Ben-Hur; Zvi Vaknin; David F Schneider; Bruce J Aronow; Ronald S Goldstein; Peter Hohenstein; Benjamin Dekel Journal: EMBO Mol Med Date: 2013-09-02 Impact factor: 12.137